Polisan NTFF

LLC NTFF Polisan is a scientific and technological pharmaceutical company organized in December 1992 by a group of specialists of the medical and biological profile of various institutions in S-Petersburg.

Performance indicators

As of the end of 2016, Polisan is one of the largest Russian manufacturers of medicines.

Areas of activity

The main activity of the company is the development, production and implementation of modern medical preparations. At the end of 2016, Polisan produces 4 original drugs. The company is an active participant in the federal FARMA-2020 program in the areas of import substitution, increasing export potential, and developing the Russian pharmaceutical substances market.

Polisan drugs are supplied to all regions of Russia, a significant part is exported to the CIS countries, Southeast Asia, Latin America and Mongolia.

Aktivs

Our own pharmaceutical plant is located in St. Petersburg, has a GMP PIC/S certificate (2015) and meets the highest requirements for the production and quality of finished medicines. Every year, the plant produces more than 15.5 million packages of drugs (2016 data), which are in demand in the medicine of critical conditions, neurology, pediatrics, oncology, and the treatment of infectious diseases. All the nomenclature of the company's products is included in the list of vital and essential drugs and is included in the standards of socially significant diseases.

At the end of 2016, Polisan is implementing projects to localize the production of drugs from international pharmaceutical companies. Also, Polisan has begun the construction of the third stage of the pharmaceutical plant and the design of a research center.

History

2023: Polisan recovered 282 million rubles from Profitmed

The manufacturer of antiviral drugs Polisan collected 282.4 million rubles from the pharmaceutical distributor Profitmed. This became known on May 22, 2023. Read more here.

2021: TAdviser interview with the head of the information security department Nikolay Kazantsev

In March 2021, the head of the information security department of Polisan Nikolay Kazantsev spoke about how the company tested and implemented the DCAP system of the domestic manufacturer SearchInform FileAuditor and why it was not arranged by other tools to protect "data at rest." Read more here.

2018: TAdviser interview

In July 2018, Evgeny Konoplev, a leading systems analyst at the Polisan pharmaceutical company, spoke in an interview with TAdviser about how the technical update procedure became a new round of development of the system on the Docsvision platform.

2016: Pfizer Drugs Launch

On December 14, 2016, Pfizer and NTFF Polisan LLC announced the launch of the production of experimental batches of Pfizer drugs at the facilities of NTFF Polisan LLC.

On January 25, 2016, in St. Petersburg in Smolny, an agreement was signed between Pfizer and NTFF Polisan LLC in a solemn atmosphere on the production of three Pfizer drugs at the Polisan plant. After the completion of the technological transfer process in Russia, NTFF Polisan LLC will begin production of an original drug to reduce blood cholesterol and reduce the risk of cardiovascular complications, an innovative tablet drug for the treatment of rheumatoid arthritis and plaque psoriasis, as well as an antibacterial drug for the treatment of nosocomial infections.

To date, the companies have transferred technology and analytical methods, selected and supplied the necessary additional technological and engineering equipment, and reconstructed the existing tablet production site of the pharmaceutical plant NTFF Polisan LLC to ensure the possibility of producing localized drugs.

In October 2016, placebo batches were developed, and in December 2016, the companies launched the production of pilot production batches of drugs.

Sofya Kadykova, CEO of Pfizer in Russia:

a large amount of work has been done to localize the production of three Pfizer drugs. The project is executed according to the approved plan. Russian patients will be able to use our drugs manufactured in the Russian Federation in 2018. The transfer of production technology is a complex process in which, in addition to equipment and production processes, people are important. We are pleased that this project is not just an effective team of highly professional specialists Polisan and Pfizer, but people with high involvement, dedication and responsibility for the result. "

General Director of NTFF Polisan LLC Alexander Borisov:

"Today we summarize the interim outcome of the project on the transfer of Pfizer drug production technology. In the 11 months since the signing of the cooperation agreement, a lot of work has been done by Polisan and Pfizer specialists. In such a short time, the installation and validation of the latest production line, which we solemnly launched today, was carried out. In the process of implementing the project, our team has gained great experience and new knowledge. We are confident that thanks to the joint efforts of Polisan and Pfizer, the project will be implemented in full and within the specified time frame. "

A localized drug for the treatment of dyslipidemia is one of the most well-studied drugs from the statin class. The results of numerous clinical studies indicate that statins significantly reduce cardiovascular morbidity and mortality and, in accordance with international and domestic guidelines for the treatment of patients with statin dyslipidemia, are the first choice drugs for the primary and secondary prevention of cardiovascular complications.

The drug to treat rheumatoid arthritis is the first anti-rheumatic drug in a new class of drugs known as Janus kinase inhibitors and the first new oral disease modifying drug to treat rheumatoid arthritis in the last 10 years. It is approved for the therapy of rheumatoid arthritis with an inadequate response to one or more basic anti-inflammatory drugs (DMARDs). This drug is the first oral drug with efficacy comparable to biologics. Unlike existing genetically engineered biological drugs (GEBDs), which often require the involvement of medical personnel for administration, it can be used completely on an outpatient basis, with periodic medical supervision.

Localized synthetic antibacterial drug, belongs to a new class of antimicrobial agents - oxazolidinones, active in vitro against aerobic gram-positive bacteria, some gram-negative bacteria and anaerobic microorganisms, including Staphylococcus spp. (including MRSA and MRSE), Enterococcus spp. (including vancomycin-resistant strains), S.pneumoniae (including ATM), Streptococcus spp., Nocardia spp., Corynebacterium spp., L.monocytogenes, Clostridium spp., Peptostreptococcus spp. No cross-resistance was observed with other antimicrobial classes.